Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. WuXi Biologics (Cayman) Inc.
  6. Summary
    2269   KYG970081173

WUXI BIOLOGICS (CAYMAN) INC.

(2269)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Hong Kong Stock Exchange
11/22/2021 11/23/2021 11/24/2021 11/25/2021 11/26/2021 Date
105.7 101.3 104 104.1 103.4 Last
19708150 26324600 10060340 7784138 9097511 Volume
-4.43% -4.16% +2.67% +0.10% -0.67% Change
Estimated financial data (e)
Sales 2021 9 689 M 1 516 M 1 516 M
Net income 2021 3 012 M 471 M 471 M
Net cash position 2021 5 818 M 910 M 910 M
P/E ratio 2021 118x
Yield 2021 -
Sales 2022 14 288 M 2 235 M 2 235 M
Net income 2022 4 282 M 670 M 670 M
Net cash position 2022 6 146 M 962 M 962 M
P/E ratio 2022 82,7x
Yield 2022 -
Capitalization 360 B 56 285 M 56 289 M
EV / Sales 2021 36,5x
EV / Sales 2022 24,8x
Nbr of Employees 7 686
Free-Float 84,4%
More Financials
Company
WUXI BIOLOGICS (CAYMAN) INC. is an investment holding company. The Company along with its subsidiaries is mainly engaged in the discovery, research and development, manufacturing and sales of biologics products. The Company’s primary products include the clinical active pharmaceutical ingredients, sterile liquid preparations, freeze-dried preparations, as well as small molecules antibiotics for injection drugs.... 
Read more
Sector
Pharmaceuticals
Calendar
03/21Earnings Release
More about the company
Ratings of WuXi Biologics (Cayman) Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about WUXI BIOLOGICS (CAYMAN) INC.
11/23WUXI BIOLOGICS CAYMAN : First GMP Production at 24,000L Line of MFG5 Facility Successfully..
PU
11/22WuXi Biologics Announces Completion of GMP Production At 24,000L Line of Its Drug Subst..
CI
11/09Hong Kong shares close higher as healthcare stocks rebound
RE
11/09Shanghai stocks flat as new lending tool fails to excite investors
RE
11/02Wuxi Biologics CFO Retires; Co-CFO to Take Over
MT
11/01WuXi Biologics Inc. Announces Chief Financial Officer Changes
CI
11/01Hong Kong shares close lower as tech, healthcare stocks weigh
RE
10/31China's blue-chip shares fall on hit from recent COVID-19 outbreaks
RE
10/31WuXi Biologics Launches a New GMP Commercial Drug Product Facility
AQ
10/31Wuxi Biologics Launches New GMP Commercial Drug Product Facility
CI
10/27WuXi Biologics Completes GMP Inspection by Health Canada for Drug Substance Facility
CI
10/25Hong Kong shares close flat as gains in energy, materials offset realty losses
RE
10/25Shanghai stocks boosted by environmental protection firms; property stocks down
RE
10/18CHINA EVERGRANDE : Hong Kong shares close higher despite China's weak growth data
RE
10/08Hong Kong shares close 0.6% higher as tech and financial stocks gain
RE
More news
News in other languages on WUXI BIOLOGICS (CAYMAN) INC.
11/02Le directeur financier de Wuxi Biologics prend sa retraite ; le co-directeur financier ..
10/04UPDATE/MÄRKTE ASIEN/Hongkong sehr schwach - Sydney folgt fester US-Vorlage
09/30Sihuan Pharma et WuXi Bio Units vont collaborer sur un candidat médicament contre le ca..
08/23Le bénéfice de Wuxi Biologics bondit de 150 % et le chiffre d'affaires fait plus que do..
04/27MÄRKTE ASIEN/Wenig Bewegung - Musik spielt bei Einzelwerten
More news
Analyst Recommendations on WUXI BIOLOGICS (CAYMAN) INC.
More recommendations
Analysis
Pfizer to halt biosimilar output in China, sell assets to WuXi Biologics
Chart WUXI BIOLOGICS (CAYMAN) INC.
Duration : Period :
WuXi Biologics (Cayman) Inc. Technical Analysis Chart | 2269 | KYG970081173 | MarketScreener
Technical analysis trends WUXI BIOLOGICS (CAYMAN) INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 26
Last Close Price 84,76 CNY
Average target price 129,57 CNY
Spread / Average Target 52,9%
EPS Revisions
Managers and Directors
Zhi Sheng Chen Chief Executive Officer & Executive Director
Ming Tu Chief Financial Officer & Executive Vice President
Ge Li Non-Executive Chairman
Weichang Zhou Executive Director, Chief Technology Officer & EVP
William Robert Keller Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
WUXI BIOLOGICS (CAYMAN) INC.0.58%56 285
CSL LIMITED10.18%101 196
SAMSUNG BIOLOGICS CO.,LTD.5.33%48 100
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.-0.80%35 680
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-12.87%32 261